Literature DB >> 26424938

Improving compliance with cervical cancer screening guidelines.

Jessica Langsjoen1, Cara Goodell1, Eduardo Castro1, Jen Thomas1, Thomas J Kuehl1, Hania Wehbe-Janek1, Meghan Hinskey1.   

Abstract

Current cervical cancer screening guidelines for the care of healthy women include HPV cotesting with all Papanicolaou (Pap) smears after the age of 30. To improve compliance with current guidelines, we instituted two processes: first, simplifying the ordering process to a single order for Pap smear plus HPV cotesting using an electronic medical record system (EMR); and second, providing education for clinic staff. Baseline and postintervention data were collected by retrospective chart review. Patients were selected during three intervals: prior to the transition to Epic EMR, after the transition to Epic, and after an educational intervention. Compliance with standard guidelines was evaluated in relation to the trial intervals, type of provider, patient age, and duration from the previous Pap smear. Provider type was analyzed by considering gynecologists versus nongynecologist providers, and physicians versus mid-level providers. Overall, the percentage of compliance with HPV test ordering did not differ (P = 0.21) between intervals. Univariate analyses performed to identify factors likely to be associated with the practice of ordering HPV cotesting only involved the type of provider. In conclusion, transition to Epic and a training session had minimal impact on compliance with ordering HPV cotesting at the time of a Pap smear except among family practice physicians, who did significantly improve their compliance rate. Gynecologists and mid-level providers were more compliant with ordering HPV cotesting throughout, but did not significantly improve after the interventions.

Entities:  

Year:  2015        PMID: 26424938      PMCID: PMC4569221          DOI: 10.1080/08998280.2015.11929305

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  10 in total

1.  FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Authors:  Ralph P Insinga; Andrew G Glass; Evan R Myers; Brenda B Rush
Journal:  Med Decis Making       Date:  2007-06-21       Impact factor: 2.583

3.  Trade-offs in cervical cancer prevention: balancing benefits and risks.

Authors:  Natasha K Stout; Jeremy D Goldhaber-Fiebert; Jesse D Ortendahl; Sue J Goldie
Journal:  Arch Intern Med       Date:  2008-09-22

4.  ACOG Practice Bulletin Number 131: Screening for cervical cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

5.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  L Stewart Massad; Mark H Einstein; Warner K Huh; Hormuzd A Katki; Walter K Kinney; Mark Schiffman; Diane Solomon; Nicolas Wentzensen; Herschel W Lawson
Journal:  Obstet Gynecol       Date:  2013-04       Impact factor: 7.661

6.  A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia.

Authors:  Mark Schiffman; Ana Cecilia Rodriguez; Zigui Chen; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Rob Desalle; Brian Befano; Kai Yu; Mahboobeh Safaeian; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Diane Solomon; Philip E Castle; Robert D Burk
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

7.  Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer.

Authors:  Hui-Chi Chen; Mark Schiffman; Ching-Yu Lin; Mei-Hung Pan; San-Lin You; Li-Chung Chuang; Chang-Yao Hsieh; Kai-Li Liaw; Ann W Hsing; Chien-Jen Chen
Journal:  J Natl Cancer Inst       Date:  2011-09-06       Impact factor: 13.506

Review 8.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.

Authors:  F Xavier Bosch; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2003

9.  The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up.

Authors:  E Maissi; T M Marteau; M Hankins; S Moss; R Legood; A Gray
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Authors:  Cosette M Wheeler; William C Hunt; Nancy E Joste; Charles R Key; Wim G V Quint; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

  10 in total
  3 in total

1.  Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative.

Authors:  Ladan Golestaneh; Joel Neugarten; William Southern; Faraj Kargoli; Amanda Raff
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

2.  Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26year old females.

Authors:  Jacqueline M Hirth; Yu-Li Lin; Yong-Fang Kuo; Abbey B Berenson
Journal:  Prev Med       Date:  2016-04-13       Impact factor: 4.018

3.  Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.

Authors:  Hillary Hosier; Sangini S Sheth; Carlos R Oliveira; Lauren E Perley; Alla Vash-Margita
Journal:  Am J Obstet Gynecol       Date:  2021-07-10       Impact factor: 8.661

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.